2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.
JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly (LLY) announced disappointing preliminary sales numbers, lowering its investor guidance ...
Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...
Pfizer announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with Bacillus Calmette-Guerin ...
Pfizer also has high hopes for PD-1/PD-L1 inhibitor sasanlimab for non-muscle invasive bladder cancer in the CREST study, and CD3xBCMA bispecific Elrexfio (elranatamab) in MagnetisMM-5 as a ...
A Phase II Clinical Trial of Neoadjuvant Sasanlimab and Stereotactic Body Radiation Therapy as an in Situ Vaccine for Cisplatin Ineligible Muscle Invasive Bladder Cancer EAU 2024: Challenging the ...
A 6.5-month-old boy with the rare inherited urea cycle disorder ornithine transcarbamylase (OTC) deficiency has responded positively in a targeted in vivo gene editing trial, in which a correct copy ...
The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience.
House G.O.P. Floats Medicaid Cuts and More to Finance Trump’s Huge Agenda President Trump wants a massive tax cut and immigration crackdown bill. Republicans must decide what to cut to help pay ...